<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Proliferative <z:e sem="disease" ids="C0042373" disease_type="Disease or Syndrome" abbrv="">angiopathy</z:e> represents the morphological basis of delayed <z:e sem="disease" ids="C0265110" disease_type="Disease or Syndrome" abbrv="">cerebral vasospasm</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>The initial vasoconstriction and endothelial damage of the vasospastic arteries leads to an exaggerated response of the smooth muscle cells within the media leading to subintimal thickening and myonecrosis </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="5" ids="28304">Heparin</z:chebi> reduces the exposure of the media to platelet derived growth factor, a <z:chebi fb="0" ids="52290">mitogen</z:chebi> from aggregating platelets responsible for the migration and proliferation of the myofibroblasts </plain></SENT>
<SENT sid="3" pm="."><plain>Since systemic <z:chebi fb="5" ids="28304">heparin</z:chebi> in the setting of a <z:hpo ids='HP_0002138'>subarachnoid haemorrhage</z:hpo> would be unacceptable, we have tested the effect of <z:chebi fb="5" ids="28304">heparin</z:chebi> on proliferative <z:e sem="disease" ids="C0042373" disease_type="Disease or Syndrome" abbrv="">angiopathy</z:e> by injecting autologous non-heparinized blood into two groups of rats (N = 12 each) and then inject the <z:chebi fb="5" ids="28304">heparin</z:chebi> into the spinal fluid of one group after one hour </plain></SENT>
<SENT sid="4" pm="."><plain>We were able to show histologically that intracisternal <z:chebi fb="5" ids="28304">heparin</z:chebi> injection after the <z:hpo ids='HP_0002138'>subarachnoid haemorrhage</z:hpo> has reduced the vascular wall changes to a great degree </plain></SENT>
<SENT sid="5" pm="."><plain>Heparinization of the cerebrospinal fluid carried out in conjunction with early operation for <z:hpo ids='HP_0002617'>aneurysms</z:hpo> may be a promising approach to prevent the morbid complications of SAH in the clinical setting </plain></SENT>
</text></document>